The University of Chicago Header Logo

Connection

Walter M. Stadler to Neoplasms

Back to Details
This is a "connection" page, showing publications Walter M. Stadler has written about Neoplasms.
Walter M. Stadler
Connection Strength
2.449
Neoplasms
  1. There Is More to Length of Survival Than Survival: Endpoints in Oncology Trials. Clin Cancer Res. 2024 Aug 01; 30(15):3098-3099.
    View in: PubMed
    Score: 0.326
  2. Enrollment Barriers for Molecular Targeted Trials. JAMA Oncol. 2023 06 01; 9(6):863-864.
    View in: PubMed
    Score: 0.301
  3. Knowledge and distress in complex cancer care. Cancer. 2022 04 01; 128(7):1359-1360.
    View in: PubMed
    Score: 0.272
  4. No interest, no conflict. Cancer. 2020 08 15; 126(16):3627-3628.
    View in: PubMed
    Score: 0.245
  5. Prognosis and prediction in a Facebook world. Cancer. 2009 Dec 01; 115(23):5368-70.
    View in: PubMed
    Score: 0.118
  6. Other paradigms: randomized discontinuation trial design. Cancer J. 2009 Sep-Oct; 15(5):431-4.
    View in: PubMed
    Score: 0.116
  7. Fuzzy thinking on biomarkers. Urol Oncol. 2007 Mar-Apr; 25(2):97-100.
    View in: PubMed
    Score: 0.098
  8. Development of growth inhibitory agents in urological and other malignancies. BJU Int. 2006 Sep; 98(3):497-502.
    View in: PubMed
    Score: 0.093
  9. New targets, therapies, and toxicities: lessons to be learned. J Clin Oncol. 2006 Jan 01; 24(1):4-5.
    View in: PubMed
    Score: 0.089
  10. Optimizing the doses of cancer drugs after usual dose finding. Clin Trials. 2024 Jun; 21(3):340-349.
    View in: PubMed
    Score: 0.078
  11. Developing drugs that do not cause tumor regression. Clin Adv Hematol Oncol. 2003 Nov; 1(11):654-5.
    View in: PubMed
    Score: 0.077
  12. Drug dosing in cancer patients with decreased kidney function: A practical approach. Cancer Treat Rev. 2021 Feb; 93:102139.
    View in: PubMed
    Score: 0.063
  13. Development of target-based antineoplastic agents. Invest New Drugs. 2000 Feb; 18(1):7-16.
    View in: PubMed
    Score: 0.060
  14. Angiogenesis inhibitors. Curr Oncol Rep. 2000 Jan; 2(1):11-6.
    View in: PubMed
    Score: 0.059
  15. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology. Cancer. 2018 07 15; 124(14):3052-3065.
    View in: PubMed
    Score: 0.053
  16. Predicting Acute Renal Injury in Cancer Patients Receiving Cisplatin Using Urinary Neutrophil Gelatinase-Associated Lipocalin and Cystatin C. Clin Transl Sci. 2018 07; 11(4):420-427.
    View in: PubMed
    Score: 0.053
  17. Pharmacogenomics in early-phase oncology clinical trials: is there a sweet spot in phase II? Clin Cancer Res. 2012 May 15; 18(10):2809-16.
    View in: PubMed
    Score: 0.035
  18. Advantages of genomic complexity: bioinformatics opportunities in microRNA cancer signatures. J Am Med Inform Assoc. 2012 Mar-Apr; 19(2):156-60.
    View in: PubMed
    Score: 0.034
  19. A phase I study of sirolimus and bevacizumab in patients with advanced malignancies. Eur J Cancer. 2011 Jul; 47(10):1484-9.
    View in: PubMed
    Score: 0.032
  20. Portable filter-based microdevice for detection and characterization of circulating tumor cells. Clin Cancer Res. 2010 Oct 15; 16(20):5011-8.
    View in: PubMed
    Score: 0.031
  21. A phase I study of continuous infusion cilengitide in patients with solid tumors. Invest New Drugs. 2012 Apr; 30(2):604-10.
    View in: PubMed
    Score: 0.031
  22. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res. 2010 Mar 15; 16(6):1745-55.
    View in: PubMed
    Score: 0.030
  23. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res. 2009 Oct 01; 15(19):6250-7.
    View in: PubMed
    Score: 0.029
  24. A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies. Clin Cancer Res. 2009 Feb 15; 15(4):1428-34.
    View in: PubMed
    Score: 0.028
  25. An initial report of a radiation dose-escalation trial in patients with one to five sites of metastatic disease. Clin Cancer Res. 2008 Aug 15; 14(16):5255-9.
    View in: PubMed
    Score: 0.027
  26. A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors. Ann Oncol. 2005 Jun; 16(6):958-65.
    View in: PubMed
    Score: 0.021
  27. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies. Cancer. 2001 Sep 15; 92(6):1567-76.
    View in: PubMed
    Score: 0.017
  28. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin Cancer Res. 2001 May; 7(5):1214-20.
    View in: PubMed
    Score: 0.016
  29. Construction of a 2.8-megabase yeast artificial chromosome contig and cloning of the human methylthioadenosine phosphorylase gene from the tumor suppressor region on 9p21. Proc Natl Acad Sci U S A. 1995 Jul 03; 92(14):6489-93.
    View in: PubMed
    Score: 0.011
  30. Activities and accomplishments of the cancer and leukemia group B genitourinary committee. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3596s-600s.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.